SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy in autoimmune diseases. JANX011 is the first program from Janux’s proprietary Adaptive Immune Response Modulator (ARM) platform to enter clinical development. The ARM platfo
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
